Investor Overview
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of partnered drug programs by advancing them through to Phase III in a cost-efficient manner.
Development programs are designed and driven by a leadership team that collectively has more than 75 years of experience in all areas of drug development. The Furiex model has proven success, with two products on the market and three compounds in development.
Furiex Pharmaceuticals has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets. The company is well-capitalized with a strong cash position and committed to sustainable growth, value creation and long-term profitability.
Our strategy is to leverage our drug development experience to in-license, develop and commercialize novel early-stage drug candidates that address medical conditions with large markets and demand for new medicines. The key elements of our strategy include:
- Advance the clinical development of the current drug candidates in our pipeline. We plan to advance drug candidates based on the results of preclinical and clinical testing and assessment of market potential.
- In-license or acquire additional early-stage compounds. The in-licensing of additional candidates in order to expand our portfolio and therefore increase long-term revenue opportunities is an objective of our company.
- Establish strategic commercialization collaborations. We plan to develop and commercialize our drug candidates through partnering or licensing arrangements such as those with Janssen-Cilag for Priligy® and Takeda for Nesina®. This strategy allows us to focus on our core development strengths and leverage the resources and commercialization capabilities already in place at our collaborators.
Furiex Pharmaceuticals was recently added to the Russell 2000® Index and the Russell Microcap Index. Russell indexes are widely used by investment managers and institutional investors for both index funds and as benchmarks for passive and active investment strategies. Inclusion in the indexes will raise our profile and generate greater interest in our stock at an institutional investor level. This reflects our continued positive momentum and efforts to increase shareholder value.
The Russell 2000 index measures the performance of the small-cap investment of the U.S. equity universe. The Russell 2000 Index is a subset of the Russell 3000® Index representing approximately 8 percent of the total market capitalization of that index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership.
The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. It makes up less than 3 percent of the U.S. equity market. It includes 1,000 of the smallest securities in the small-cap Russell 2000® index based on a combination of their market cap and current index membership and it includes the next 1,000 securities.